Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Influenza virus matrix protein 1 (M1) forms the virion’s structural scaffold beneath the envelope and regulates assembly, RNA export, and disassembly via pH-sensitive conformational changes. Matrix protein 2 (M2) is an integral membrane ion channel required for viral uncoating and assembly, and is the target of adamantane-class antivirals. Nucleoprotein (NP) of both influenza A and B viruses encapsidates the viral RNA, facilitates nuclear import, and is essential for genome packaging and transcription. These proteins are critical for viral replication and are prominent targets in antiviral drug development and diagnostics.
Drugs targeting M2 inhibit the M2 ion channel, preventing virus uncoating and replication. Inhibitors targeting M1/NP aim to block protein-protein interactions, assembly, or replication, primarily in experimental settings.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Influenza virus proteins M1, M2, NP-A, and NP-B (M1, M2, NP).